Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from patients with Essential Thrombocythemia (ET), Polycythemia Vera (PV), Primary Myelofibrosis (PMF)

ABSTRACT: Microarrays were used to assess gene expression in patients with ET, PV, and PMF before and after treatment with IFNalpha2 in a paired design.

ORGANISM(S): Homo sapiens

PROVIDER: GSE57793 | GEO | 2018/06/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Expression data from patients with Essential Thrombocythemia (ET), Polycythemia Vera (PV), Primary Myelofibrosis (PMF) (untreated)

Project description:Microarrays were used to assess gene expression in patients with ET, PV, and PMF before treatment with IFNalpha2.

2017-02-09 | GSE61629 | GEO

Expression data from patients with Essentiel Thrombocythemia (ET), Polycythemia Vera (PV), Primary Myelofibrosis (PMF) and control subjects

Project description:We used microarrays to assess gene expression in patients with ET, PV, and PMF compared to control subjects

2012-01-10 | GSE26049 | GEO

Expression data from patients with Essentiel Thrombocythemia (ET), Polycythemia Vera (PV), Primary Myelofibrosis (PMF) and control subjects

Project description:We used microarrays to assess gene expression in patients with ET, PV, and PMF compared to control subjects Total RNA was purified from whole blood and amplified to biotin-labeled aRNA and hybridized to microarray chips.

2012-01-10 | E-GEOD-26049 | biostudies-arrayexpress

Histomorphological responses after therapy with pegylated interferon ?-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Project description: Not available

| S-EPMC5679503 | biostudies-literature

Changes of miRNA expression in granulocytes of patients with polycythemia vera (PV) and essential thrombocythemia (ET) receiving INCB018424 in a Phase 2 study

2012-09-26 | GSE32194 | GEO

MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia.

Project description: Not available

| S-EPMC4542760 | biostudies-literature

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Project description: Not available

| S-EPMC4654629 | biostudies-literature

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Project description: Not available

| S-EPMC6768916 | biostudies-literature

Gene Expression Profiling in Polycythemia Vera (PV)

Project description:To define the molecular abnormalities at the stem cell level in polycythemia vera (PV), we examined global gene expression in circulating CD34+ cells from 19 JAK2 V617F-positive PV patients and 6 normal individuals using Affymetrix oligonucleotide microarray technology. We observed that CD34+ cell gene expression not only differed between the PV patients and the normal controls but also between men and women PV patients. Based on these gender-specific differences in gene expression, we were able to identify 102 genes differentially regulated concordantly by both men and women, which likely represent a core set of genes whose dysregulation is involved in the pathogenesis of PV. Gene expression was verified by Q-PCR of patient CD34+ cell RNA. Using the 102 gene set and unsupervised hierarchical clustering, the 19 PV patients could be separated in two groups that differed significantly with respect to hemoglobin level, thrombosis frequency, splenomegaly, splenectomy or chemotherapy exposure, leukemic transformation and overall survival. These results were confirmed using top scoring pairs, which identified a different set of 29 genes that independently segregated the 19 patients into the same two clinical groups: those with an aggressive form of the disease (7 patients), and those with an indolent form (12 patients).

2014-08-29 | GSE47018 | GEO

Changes of miRNA expression in granulocytes of patients with polycythemia vera (PV) and essential thrombocythemia (ET) receiving INCB018424 in a Phase 2 study

Project description:A global microRNA expression profile was obtained from gradient-purified granulocytes (>95% pure) collected at the time of screening and at cycle 4 of treatment Protocol #18424-256 is a Phase 2 study of the JAK1 and JAK2 inhibitor INCB01842 in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea; The aim was to to determine whether treatment with INC180424 was associated with changes in the global microRNA expression profile we compared granulocytes collected at baseline (screening) and at cycle 4

2012-09-26 | E-GEOD-32194 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data